Chinese insulin maker says its GLP-1 beat Ozempic at lowering blood sugar, body weight in phase 2

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) and body weight in a phase 2 trial in patients with type 2 diabetes, the company announced in an Oct. 15 release.